Cargando…

P908: FACTORS ASSOCIATED WITH THE CLINICAL PROGNOSTIC PERFORMANCE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY NEXT GENERATION FLOW CYTOMETRY IN MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Nandakumar, B., Baranwal, A., Ebraheem, M., Olteanu, H., Shi, M., Kumar, S., Gonsalves, W., Jevremovic, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431253/ http://dx.doi.org/10.1097/01.HS9.0000846504.49611.cf

Ejemplares similares

Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia
por: Salama, Mohamed E., et al.
Publicado: (2022)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2018)

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
por: Terpos, Evangelos, et al.
Publicado: (2019)

Minimal residual disease negativity by next‐generation flow in non‐CR myeloma patients
por: Kim, Sung‐Min, et al.
Publicado: (2020)

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
por: Foureau, David M., et al.
Publicado: (2023)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

Eight‐color multiparameter flow cytometry (EuroFlow‐NGF) is as sensitive as next‐generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma
por: Urushihara, Ryota, et al.
Publicado: (2023)

Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry
por: Ho, Caleb, et al.
Publicado: (2021)

Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
por: Kim, Hyun-Young, et al.
Publicado: (2022)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
por: Rasche, L, et al.
Publicado: (2018)

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma
por: Silvennoinen, R, et al.
Publicado: (2014)

Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation
por: Dal Bó, Suzane, et al.
Publicado: (2013)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
por: Oliva, Stefania, et al.
Publicado: (2021)

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
por: Oliva, Stefania, et al.
Publicado: (2023)

Flow Cytometry: The Next Revolution
por: Robinson, J. Paul, et al.
Publicado: (2023)

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
por: Boeckle, D., et al.
Publicado: (2022)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Multicentric standardization of minimal/measurable residual disease in B‐cell precursor acute lymphoblastic leukaemia using next‐generation flow cytometry in a low/middle‐level income country
por: Ikoma‐Colturato, Maura R. V., et al.
Publicado: (2022)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR
por: Yao, Qiumei, et al.
Publicado: (2021)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

MPV908A-ADC driver: The MPV908A ADC VMEbus board driver under LynxOS
por: Abie, Habtamu, et al.
Publicado: (1992)

Growth of small fatigue cracks in Incoloy-908
por: Mei, Z, et al.
Publicado: (1993)

The mpv908 : more about using and testing it
por: Heinze, W
Publicado: (1993)

MPV908 Analog I/O Driver
por: Abie, H, et al.
Publicado: (1993)

MON-908 Carcinoid Causing Catastrophic Calcemia
por: Franquemont, Stephanie, et al.
Publicado: (2020)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
por: Krzywdzińska, Agnieszka, et al.
Publicado: (2021)

Flow Cytometry and Polymerase Chain Reaction-Based Analyses of Minimal Residual Disease in Chronic Lymphocytic Leukemia
por: Uhrmacher, Sabrina, et al.
Publicado: (2010)

Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients
por: Zver, Tristan, et al.
Publicado: (2022)

Prognostic Significance of Circulating Plasma Cells by Multi-Parametric Flow Cytometry in Light Chain Amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2018)

Detection of minimal residual disease by next generation sequencing in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lok7ds5e2oiinm46dnr1dmq7b0